A new study
in mice and human tissue hints at a way to keep cancer from spreading.
Cancer cells
may suddenly "reawaken" and spread throughout the body after years of
lying dormant. Now, scientists may be closer to understanding why.
In a new
study published Monday (Dec. 13) in Nature Cancer, scientists found that in
mice, dormant cancer cells were surrounded by larger amounts of a specific type
of collagen, the main protein that makes up connective tissue, than active
cancer cells.
The team
also examined this collagen, known as type III collagen, in samples from human
patients with head and neck cancer. Patients whose cancer had spread to their
lymph nodes tended to have primary tumors with less type III collagen nearby
than patients with no cancer in their lymph nodes, suggesting that cancer with
less type III collagen might spread more easily to other parts of the
body. n their mouse models, the scientists found that the type III
collagen surrounding dormant cancer cells seems to decrease over time, and the
cancer cells become active again. The collagen changes its structure during this
process, becoming less wavy and more linear. The researchers also identified a
specific process, called a signaling pathway, through which this collagen from
the tumor changes the bodys chemistry and keeps the nearby cancer cells
dormant. They discovered that disrupting this process causes cancer cells to
"reactivate."
These
distinct changes in type III collagen could be a useful marker for determining
if cancer is more likely to spread, or metastasize, said study senior author
Jose Javier Bravo-Cordero, an associate professor of medicine, hematology and
medical oncology at the Tisch Cancer Institute at Mount Sinai in New York. The
researchers also found that in mice, replacing the tumors with scaffolds made
of this collagen could prevent metastatic tumor growth, which, if it were
effective in humans, could serve as a future cancer treatment.
In the new
research, the team used mouse models of head and neck cancer and breast cancer
to study both active and dormant cancer cells. When introduced to the mice, the
active cells formed tumors and the cancer spread, while the dormant cancer
cells formed small clumps that remained in isolated areas and did not grow or
spread. Among other tools, the researchers used a specialized form of
microscopy to observe cancer cells inside live mice in real time. Bravo-Cordero
compared the method to using a security camera in a store. Looking at still
images taken by a security camera individually or out of sequence wouldnt
necessarily catch a thief, he said, but a video recording would tell a more
complete story.
"That's
what we're trying to do with the cancer cells," Bravo-Cordero told Live
Science. "We want to film them in real time so we can understand their
process and their behavior." In this way, the team spotted the differences
in collagen between the tumor types.
"If you
have a tumor that has a tendency to lose collagen expression, over time the
cells that disseminate may be more efficient in restoring growth and forming
metastases than the ones that overexpress collagen," Bravo-Cordero said.
To test
whether type III collagen could prevent cancer metastases and lessen cancer
growth in mice, the researchers introduced type III collagen into the mice in
several ways, including by injecting both cancer cells and the collagen into
the animals at the same time. The resulting tumors grew more slowly than tumors
in mice injected with only cancer cells. In a different experiment, the
researchers also placed a tiny, bioengineered scaffold loaded with type III
collagen into an area where they had removed a tumor from the mice. Only
20% of the mice with the scaffolds had the cancer return in that area, versus
80% in the control group.
"In
that condition, what we see is that we can prevent the recurrence of those
tumors," said Bravo-Cordero, by "forcing the cells into the dormant
state." If the same thing held true in humans, a method like this could
potentially be used as a cancer treatment, he said.
Of course,
there is no guarantee the same would hold true in humans. Theres also no
guarantee that type III collagen would have the same role for multiple types of
cancer, or even for different types of dormant cancer cells.
Just as
"human cancers are very different from one patient to the other, it's
almost certainly the case that there will be great heterogeneity in the
mechanisms of dormancy," said Dr. Lewis Chodosh, the chairman of the
department of cancer biology at the Perelman School of Medicine at the
University of Pennsylvania, who was not involved in the study. In other words,
cancer cells likely have several ways of remaining dormant, and this may only
be one of them.
Chodosh said
a major strength of the study is the many methods the researchers used to
collect data, incorporating data from mice and human samples. But a challenge
of this type of cancer research is "understanding which of the things
discovered in experimental systems are applicable to humans and in which clinical
contexts," he said.
Future
research will help answer these questions, as well as others, such as how long
such collagen treatments could keep the cancer cells dormant. Still, the new
research brings us closer to understanding one of the most mysterious and
deadly aspects of cancer growth.
'This is an
understudied area in cancer biology that has critical relevance to cancer
patients," Chodosh said.
Originally published on Live Science.